ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss	Adnexal Diseases, Carcinoma, Endometrioid, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, carcinoma, carcinosarcoma, cervix disorder, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, mixed neoplasm, neoplasm, ovarian cancer, ovarian disorder, sarcoma, uterine disorder	Active, not recruiting	Phase 2	2026-02-20		NCT04065269

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Cancer Research UK	59
Institute of Cancer Research, United Kingdom	59

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Imperial College NHS Trust	London	United Kingdom	3
Princess Margaret Cancer Centre	Toronto	Canada	145
Royal United Hospital	Bath	United Kingdom	12
The Beatson	Glasgow	United Kingdom	3
The Christie	Manchester	United Kingdom	7
The Ottawa Hospital Cancer Centre	Ottawa	Canada	26
The Royal Marsden NHS Foundation Trust	London	United Kingdom	41
University of Montreal Hospital Centre	Montreal	Canada	1
Western General Hospital	Edinburgh	United Kingdom	23